全外显子组分子尸检中变异解读的重要性:基于人群的病例系列
该研究纳入2012至2013年伊利诺伊州库克县25例1至40岁不明原因猝死(SUDY)病例,常规尸检阴性或模棱两可,行全外显子组分子尸检分析99个猝死易感基因,按美国医学遗传学与基因组学学会(ACMG)指南判读超罕见非同义变异。结果显示16/25(64%)携带超罕见非同义变异,7/25(28%)检出致病/可能致病变异,但仅4/25(16%)的6个变异与尸检表型一致且具临床可操作性。
要点
- 全外显子组分子尸检可检出SUDY病例中的潜在致病变异,但需系统判读。
- 28%病例检出致病/可能致病变异,仅16%与尸检表型一致且具临床可操作性。
- 变异判读对存活家属的准确照护至关重要。
核心结论
- 全外显子组分子尸检结合基因特异性监测可有效检测SUDY病例中的潜在致病变异,但系统变异判读对确保存活家属获得准确适当照护至关重要。
研究设计与样本
- 基于人群的病例系列,纳入2012年1月至2013年12月伊利诺伊州库克县25例1至40岁SUDY连续病例(平均死亡年龄27±5.7岁;13例白人,12例黑人),常规尸检阴性(n=16)或模棱两可(n=9)后行全外显子组分子尸检,分析99个猝死易感基因。
主要发现
- 16/25(64%)病例检出27个超罕见非同义变异,黑人中9/12(75%)携带,白人7/13(54%)。
- 按ACMG指南,27个变异中10个为致病/可能致病,见于7/25(28%)病例。
- 尸检阴性病例中5/16(31%)检出致病/可能致病变异,模棱两可心肌病病例中2/6(33%)检出。
- 4/25(16%)病例的6个致病/可能致病变异与尸检表型一致,被认为具临床可操作性。
临床怎么用
- 对SUDY病例行全外显子组分子尸检时,应依据ACMG指南系统判读变异,优先关注与尸检表型一致的致病/可能致病变异以指导家属照护。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Potentially lethal cardiac channelopathies/cardiomyopathies may underlie a substantial portion of sudden unexplained death in the young (SUDY). The whole-exome molecular autopsy represents the latest approach to postmortem genetic testing for SUDY. However, proper variant adjudication in the setting of SUDY can be challenging. METHODS: From January 2012 through December 2013, 25 consecutive cases of SUDY from 1 to 40 years of age (average age at death 27±5.7 years; 13 white, 12 black) from Cook County, Illinois, were referred after a negative (n=16) or equivocal (n=9) conventional autopsy. A whole-exome molecular autopsy with analysis of 99 sudden death-susceptibility genes was performed. The predicted pathogenicity of ultrarare, nonsynonymous variants was determined using the American College of Medical Genetics guidelines. RESULTS: Overall, 27 ultrarare nonsynonymous variants were seen in 16/25 (64%) victims of SUDY. Among black individuals, 9/12 (75%) had an ultrarare nonsynonymous variant compared with 7/13 (54%) white individuals. Of the 27 variants, 10 were considered pathogenic or likely pathogenic in 7/25 (28%) individuals in accordance with the American College of Medical Genetics guidelines. Pathogenic/likely pathogenic variants were identified in 5/16 (31%) of autopsy-negative cases and in 2/6 (33%) victims of SUDY with equivocal findings of cardiomyopathy. Overall, 6 pathogenic/likely pathogenic variants in 4/25 (16%) cases were congruent with the phenotypic findings at autopsy and therefore considered clinically actionable. CONCLUSIONS: Whole-exome molecular autopsy with gene-specific surveillance is an effective approach for the detection of potential pathogenic variants in SUDY cases. However, systematic variant adjudication is crucial to ensure accurate and proper care for surviving family members.
引用
- Shanks GW, Tester DJ, Ackerman JP, et al. Importance of Variant Interpretation in Whole-Exome Molecular Autopsy: Population-Based Case Series. Circulation. 2018. PMID: 29915097. doi:10.1161/CIRCULATIONAHA.117.031053
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。